Sierra Oncology Inc (OQ:SRRA)

Business Focus: Bio Therapeutic Drugs

Recent Price for SRRA
USD 2.500 +0.140 (+5.932%)
NASDAQ Delayed 15 minutes
11:09 EST
1-Day High 52-Week High P/E 1-Day Volume Mkt Cap ($Mil)
2.500 2.640 N/A 132,505 130.74
1-Day Low 52-Week Low Yield Avg. Volume  
2.360 1.100 0.0% 631,898  
Nov 08, 2017 07:00 ET
Sierra Oncology Reports Third Quarter Results
- Chk1 inhibitor SRA737 Monotherapy trial expanded to eight leading centers across the UK -- On track to provide planned SRA737 Program Update in February 2018 - - $107.8 million cash expected to fund current operating plans through approximately mid-2019 -...
Nov 08, 2017 07:00 ET
Sierra Oncology Reports Third Quarter Results
- Chk1 inhibitor SRA737 Monotherapy trial expanded to eight leading centers across the UK -- On track to provide planned SRA737 Program Update in February 2018 - - $107.8 million cash expected to fund current operating plans through approximately mid-2019 -...
Nov 07, 2017 07:00 ET
Sierra Oncology to Present at the Jefferies 2017 London Healthcare Conference
- "Beyond PARP - Next Generation DDR Therapeutics" scheduled for 4:00 p.m. GMT on November 16, 2017 -...
Nov 07, 2017 07:00 ET
Sierra Oncology to Present at the Jefferies 2017 London Healthcare Conference
- "Beyond PARP - Next Generation DDR Therapeutics" scheduled for 4:00 p.m. GMT on November 16, 2017 -...
Oct 30, 2017 07:00 ET
Sierra Oncology Reports Preclinical Data for its Chk1 Inhibitor SRA737 Supporting its Ongoing Clinical Development Strategy
- SRA737 demonstrates synergy with replication stress-inducing agents -- SRA737 plus gemcitabine efficacious in gemcitabine-resistant tumor models -- SRA737 potentiated by novel sub-therapeutic gemcitabine dosing -...
Oct 30, 2017 07:00 ET
Sierra Oncology Reports Preclinical Data for its Chk1 Inhibitor SRA737 Supporting its Ongoing Clinical Development Strategy
- SRA737 demonstrates synergy with replication stress-inducing agents -- SRA737 plus gemcitabine efficacious in gemcitabine-resistant tumor models -- SRA737 potentiated by novel sub-therapeutic gemcitabine dosing -...
Oct 25, 2017 07:00 ET
Sierra Oncology Appoints Dr. Andrew Allen to its Board of Directors
- Dr. Allen, key contributor in the advancement of PARP inhibitors, to support Sierra in developing next-generation DDR therapeutics -...
Oct 25, 2017 07:00 ET
Sierra Oncology Appoints Dr. Andrew Allen to its Board of Directors
- Dr. Allen, key contributor in the advancement of PARP inhibitors, to support Sierra in developing next-generation DDR therapeutics -...
Oct 16, 2017 13:00 ET
Sierra Oncology to Report Chk1 Inhibitor SRA737 Preclinical Data at AACR-NCI-EORTC 2017
- Chk1 inhibitor SRA737 demonstrates chemical synthetic lethality with replication stress-inducing agents, including potentiation by novel low-dose gemcitabine combination, in preclinical models of cancer -...
Oct 16, 2017 13:00 ET
Sierra Oncology to Report Chk1 Inhibitor SRA737 Preclinical Data at AACR-NCI-EORTC 2017
- Chk1 inhibitor SRA737 demonstrates chemical synthetic lethality with replication stress-inducing agents, including potentiation by novel low-dose gemcitabine combination, in preclinical models of cancer -...
Oct 11, 2017 07:00 ET
Sierra Oncology to Present at the 2017 BIO Investor Forum
- "Beyond PARP - Next Generation DDR Therapeutics" scheduled for 11:00 am PT on October 17, 2017 -...
Oct 11, 2017 07:00 ET
Sierra Oncology to Present at the 2017 BIO Investor Forum
- "Beyond PARP - Next Generation DDR Therapeutics" scheduled for 11:00 am PT on October 17, 2017 -...
Sep 20, 2017 07:00 ET
Sierra Oncology to Present at the 2017 Cantor Fitzgerald Global Healthcare Conference
- "Beyond PARP - Next Generation DDR Therapeutics" scheduled for 8:35 am ET on September 26, 2017 -...
Sep 20, 2017 07:00 ET
Sierra Oncology to Present at the 2017 Cantor Fitzgerald Global Healthcare Conference
- "Beyond PARP - Next Generation DDR Therapeutics" scheduled for 8:35 am ET on September 26, 2017 -...
Aug 15, 2017 07:00 ET
Sierra Oncology Establishes Distinguished DNA Damage Response Advisory Committee
- Leading experts in DDR biology, chemistry and medicine to help maximize the potential clinical and commercial opportunities for Sierra's drug candidates –...
Aug 15, 2017 07:00 ET
Sierra Oncology Establishes Distinguished DNA Damage Response Advisory Committee
- Leading experts in DDR biology, chemistry and medicine to help maximize the potential clinical and commercial opportunities for Sierra's drug candidates –...
Aug 10, 2017 07:00 ET
Sierra Oncology Reports Second Quarter 2017 Results
- On track to provide preliminary update from Chk1 inhibitor SRA737 clinical trials in early 2018 -...
Aug 10, 2017 07:00 ET
Sierra Oncology Reports Second Quarter 2017 Results
- On track to provide preliminary update from Chk1 inhibitor SRA737 clinical trials in early 2018 -...
Aug 02, 2017 07:00 ET
Sierra Oncology to Present at the 2017 Wedbush PacGrow Healthcare Conference
- "Beyond PARP - Next Generation DDR Therapeutics" scheduled for 1:55 pm ET on August 15, 2017 -...
Aug 02, 2017 07:00 ET
Sierra Oncology to Present at the 2017 Wedbush PacGrow Healthcare Conference
- "Beyond PARP - Next Generation DDR Therapeutics" scheduled for 1:55 pm ET on August 15, 2017 -...
Jun 05, 2017 07:00 ET
Sierra Oncology Reports Encouraging Initial Progress from Ongoing Phase 1 Clinical Trials of Chk1 Inhibitor SRA737
- Presenting two posters describing innovative trial designs leveraging Chk1 synthetic lethality at the ASCO 2017 Annual Meeting -...
Jun 05, 2017 07:00 ET
Sierra Oncology Reports Encouraging Initial Progress from Ongoing Phase 1 Clinical Trials of Chk1 Inhibitor SRA737
- Presenting two posters describing innovative trial designs leveraging Chk1 synthetic lethality at the ASCO 2017 Annual Meeting -...
May 30, 2017 07:00 ET
Sierra Oncology Granted US and EU Patents for Chk1 inhibitor SRA737
-  Selection patent issued for SRA737 covers the compound explicitly and extends initial protection out to 2033 -...
May 30, 2017 07:00 ET
Sierra Oncology Granted US and EU Patents for Chk1 inhibitor SRA737
-  Selection patent issued for SRA737 covers the compound explicitly and extends initial protection out to 2033 -...
May 24, 2017 07:00 ET
May 24, 2017 07:00 ET
May 10, 2017 07:00 ET
Sierra Oncology Receives Clearance to Enhance Ongoing Clinical Trials for SRA737
- Phase 1 monotherapy and combination clinical trials amended to focus on novel genetically-driven, prospective patient selection strategy designed to demonstrate synthetic lethality - ...
May 10, 2017 07:00 ET
Sierra Oncology Receives Clearance to Enhance Ongoing Clinical Trials for SRA737
- Phase 1 monotherapy and combination clinical trials amended to focus on novel genetically-driven, prospective patient selection strategy designed to demonstrate synthetic lethality - ...
May 09, 2017 07:00 ET
Sierra Oncology Reports First Quarter 2017 Results
 - Sierra ends Q1 with $125M to fund current operating plans through approximately mid-2019 - ...
May 09, 2017 07:00 ET
Sierra Oncology Reports First Quarter 2017 Results
 - Sierra ends Q1 with $125M to fund current operating plans through approximately mid-2019 - ...
Apr 03, 2017 07:00 ET
Sierra Oncology Collaborator ICR Reports Preclinical Synthetic Lethality Data for Chk1 Inhibitor SRA737 at AACR
- Research conducted by Professor Paul Workman supports the use of SRA737 in certain genetically defined tumors and in combination with chemotherapy -...
Apr 03, 2017 07:00 ET
Sierra Oncology Collaborator ICR Reports Preclinical Synthetic Lethality Data for Chk1 Inhibitor SRA737 at AACR
- Research conducted by Professor Paul Workman supports the use of SRA737 in certain genetically defined tumors and in combination with chemotherapy -...
Mar 02, 2017 07:00 ET
Sierra Oncology Reports 2016 Year-End Results
VANCOUVER, March 2, 2017 /CNW/ - Sierra Oncology, Inc. (NASDAQ: SRRA), a clinical stage drug development company focused on advancing next generation DNA Damage Response therapeutics for the treatment of patients with cancer, today reported its financial and operational results for the year ended December 31st, 2016....
Mar 02, 2017 07:00 ET
Sierra Oncology Reports 2016 Year-End Results
VANCOUVER, March 2, 2017 /PRNewswire/ - Sierra Oncology, Inc. (NASDAQ: SRRA), a clinical stage drug development company focused on advancing next generation DNA Damage Response therapeutics for the treatment of patients with cancer, today reported its financial and operational results for the year ended December 31st, 2016....
Feb 09, 2017 09:11 ET
Sierra Oncology Announces Pricing of Public Offering of Common Stock
VANCOUVER, Feb. 9, 2017 /CNW/ - Sierra Oncology, Inc. (NASDAQ: SRRA), a clinical stage drug development company focused on advancing next generation DNA Damage Response therapeutics for the treatment of patients with cancer, today announced the pricing of an underwritten public offering of 19,500,000 shares of its common stock at a price of $1.35 per share, with expected gross proceeds to Sierra Oncology of $26.3 million. In addition, Sierra Oncology has granted the underwriters a 30-day option to purchase up to 2,925,000 additional shares of common stock at the public offering price, less u...
Feb 09, 2017 09:11 ET
Sierra Oncology Announces Pricing of Public Offering of Common Stock
VANCOUVER, Feb. 9, 2017 /PRNewswire/ - Sierra Oncology, Inc. (NASDAQ: SRRA), a clinical stage drug development company focused on advancing next generation DNA Damage Response therapeutics for the treatment of patients with cancer, today announced the pricing of an underwritten public offering of 19,500,000 shares of its common stock at a price of $1.35 per share, with expected gross proceeds to Sierra Oncology of $26.3 million. In addition, Sierra Oncology has granted the underwriters a 30-day option to purchase up to 2,925,000 additional shares of common stock at the public offering price,...
Feb 08, 2017 16:01 ET
Sierra Oncology Announces Proposed Public Offering of Common Stock
VANCOUVER, Feb. 8, 2017 /CNW/ - Sierra Oncology, Inc. (NASDAQ: SRRA), a clinical stage drug development company focused on advancing next generation DNA Damage Response therapeutics for the treatment of patients with cancer, today announced that it intends to offer and sell, subject to market conditions, shares of its common stock in an underwritten public offering. All of the shares to be sold in the offering will be offered by Sierra Oncology. The offering is subject to market and other conditions, and there can be no assurance as to whether or when the offering may be completed, or as to ...
Feb 08, 2017 16:01 ET
Sierra Oncology Announces Proposed Public Offering of Common Stock
VANCOUVER, Feb. 8, 2017 /PRNewswire/ - Sierra Oncology, Inc. (NASDAQ: SRRA), a clinical stage drug development company focused on advancing next generation DNA Damage Response therapeutics for the treatment of patients with cancer, today announced that it intends to offer and sell, subject to market conditions, shares of its common stock in an underwritten public offering. All of the shares to be sold in the offering will be offered by Sierra Oncology. The offering is subject to market and other conditions, and there can be no assurance as to whether or when the offering may be completed, or...